Will Hemispherx BioPharma, Inc.(NYSEMKT:HEB), Rock Creek Pharmaceuticals Inc(NASDAQ:RCPI), and Johnson & Johnson(NYSE:JNJ) Improve Their Long-Term Outlooks?
New York, NY – GDP INSIDER – 10/17/2014.
This article discusses three stocks: Hemispherx BioPharma, Inc.(NYSEMKT:HEB), Rock Creek Pharmaceuticals Inc(NASDAQ:RCPI), and Johnson & Johnson(NYSE:JNJ)
Hemispherx BioPharma, Inc(NYSEMKT:HEB) currently has a bid price of $0.17 x 500 and an offer price of $0.46 x 100, figures that suggest that the company’s stock may soon fluctuate. The Philadelphia-based specialty pharmaceutical company is currently engaged in research to find a solution to the growing Ebola problem that has captured the minds and caused fear in the American public. As a result, one might see the stock’s value rise in the near future.
Rock Creek Pharmaceuticals Inc(NASDAQ:RCPI) is a Florida-based biotechnology that develops and commercializes compounds and formulations used to target inflammatory and neurological disorders. The company has seen its trading volume drop recently, falling to a figure of 516,550 yesterday after recorded a three month average volume of 879,180. Recently, Rock Creek Pharmaceuticals froze its sale of the Anatabloc and CigRx products due to unresolved issues with the FDA and the marketing of anatabine.
Johnson & Johnson(NYSE:JNJ) reported its third quarter financial results on Oct. 14th. The figures included a sales figure of $18.5 billion, a 5.1% increase in value compared to the same period during the previous fiscal year. Additionally, the company also reported net earnings and diluted earnings per share figures of $4.7 billion and $1.66, respectively. Yesterday morning, the company also announced diluted earnings per share for the fourth quarter of $0.70 per common share.
HotStockGains.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word BREAKOUT to 555888 from your cell phone.
Additionally, HotStockGains free newsletter provides market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks.
Disclosure: HotStockGains is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit http://hotstockgains.com/disclaimer/ for complete risks and disclosures.